• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Sponsored Post
    • Make a Contribution
  • Technology Events 2022-2023
  • Technology Domains
  • Technology Markets
  • Venture Capital
  • Contact
    • About

WuXi NextCODE Completes $200 Million Series C Financing

November 27, 2018 By Technologies.org Leave a Comment

Leading global sovereign and technology investors from Ireland, Singapore, US and China back its data strategy to expand the reach and power of the leading global platform in genomics

Major investments in Ireland aim to create the world’s premier genomic and medical dataset, uniquely powered to accelerate drug discovery and deliver meaningful benefits of precision medicine to global patients

WuXi NextCODE, the emerging global standard platform for genomic data, today announced the successful completion of a $200 million Series C financing.

The company completed the Series C round financing with investment from a consortium led by the Ireland Strategic Investment Fund (ISIF), which has invested $70 million in this round and was the lead shareholder in Genomics Medicine Ireland (GMI). GMI was recently acquired by WuXi NextCODE as its Irish subsidiary and business headquarters in Europe, as part of a $400 million investment program positioning Ireland as a global leader in precision medicine and advanced life sciences. Other participants in the Ireland initiative and Series C financing include WuXi NextCODE’s longtime existing shareholders Temasek, Yunfeng Capital and Sequoia Capital. This financing round follows the completion of the company’s $240 million Series B in September 2017.

“Turning the genome into a tool for better health for everyone is at heart a data challenge,” said Dr. Ge Li, chairman of WuXi NextCODE. “Just as we have enabled partners in US, in China and elsewhere, we are building in Ireland fully certified large-scale sequencing facilities integrated with our GOR database, discovery and interpretation capabilities, and strengthening our genomics and data platform with global standard. It will accelerate drug discovery and deliver meaningful benefits of precision medicine to patients in Ireland first, and eventually to people worldwide. That is our mission, and we are grateful to have the opportunity to work to realize it in Ireland.”

“The success of this financing round is an endorsement of our strategy to create the leading global platform for using the genome to improve the lives of people and patients everywhere,” said Rob Brainin, CEO of WuXi NextCODE. “This phase of our growth has a distinctly Irish focus to it, and we are creating in Ireland the world’s premier genome dataset as a uniquely powerful engine both for transforming how we discover new drugs, as well as for bringing new diagnostics, risk screens and other tools and services to the individual patients. With an investor base now too as global as our mission, we are more excited than ever to answer the confidence of our partners and participants with transformational results.”

“Through our investment in WuXi NextCODE we have been able to bring to Ireland many of the world’s biggest and most successful investors in innovation,” said Paul Saunders, Senior Investment Director at ISIF. “We have positioned GMI to play a leading role in realizing precision medicine not just in Ireland but at the European and global levels, driven by WuXi NextCODE’s renowned informatics, analytics, and track record in population-scale genomics worldwide. This is one of ISIF’s most significant investments to date in an innovation enterprise, and through it we are not only driving high-value employment and economic development, but also putting Ireland at the heart of an exciting global life sciences opportunity that we are proud to be a part of.”

WuXi NextCODE is focusing the proceeds from this round on rapidly expanding operations at GMI, and to accelerate the program to enroll and sequence the entire genome of some 400,000 people from across Ireland. This effort will position Ireland to play a leading role in the development and use of precision medicine. It aims to leverage a unique set of national characteristics — high-quality healthcare, relative genetic homogeneity, cutting-edge medical science and forward-looking policy and institutions — to innovate and deliver genome-driven improvements in health.

About WuXiNextCODE

WuXiNextCODE is an integrated global life sciences informatics company building the global standard platform for genomic data. With offices in Shanghai; Kendall Square in Cambridge, Massachusetts; Reykjavik, Iceland; and Dublin, we serve the leading population genomics, precision medicine, diagnostics and wellness initiatives and enterprises using the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, interpretation, scalable analytics, and AI and deep learning – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. Visit us on the web at www.WuXiNextCODE.com.

Related

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Infinitum Electric Raises $80M in Series D Funding Led by Riverstone Holdings to Scale Production of Sustainable Motors
  • Introducing IonQ Forte, Improving Quantum Performance with a Software-Configurable Dynamic Laser System
  • Cloudflare Unveils New SQL Database Offering
  • Cloudflare announces Workers for Platforms
  • Intel is rolling out new processors designed for data centers
  • EU moves to wean itself off Russian fossil fuels
  • A New Hydrogen-Powered Behemoth
  • BAE Systems to Bring Next-Generation Electric Drive System to Heavy-Duty Industrial Vehicle Market
  • MEMS Speakers Are Replacing Balanced Armature Speakers
  • Trends in data and analytics

Media Partners

  • VPNW
  • S3H
  • OPINT
  • Press Media Release
  • OSINT
  • Digital Market
  • Briefly

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Defense Conferences
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Opinion
  • Venture Capital

Copyright © 2015 Technologies.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT